Form 8-K - Current report:
SEC Accession No. 0000950170-25-036296
Filing Date
2025-03-10
Accepted
2025-03-10 16:13:23
Documents
13
Period of Report
2025-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20250310.htm   iXBRL 8-K 47925
2 EX-99.1 tnya-ex99_1.htm EX-99.1 154329
3 GRAPHIC img92481827_0.jpg GRAPHIC 6181
  Complete submission text file 0000950170-25-036296.txt   341471

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20250310.xsd EX-101.SCH 25873
15 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20250310_htm.xml XML 4909
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 25723840
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)